Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Alterity Therapeutics LimitedNASDAQ: ATHE

Operating Income · Q2 FY2026 · quarter ended Dec 2025

Operating income remains negative

Q2 FY2026 operating income was -A$12.82M, compared with -A$7.49M a year earlier.

Context

  • Operating income amounted to 268.0% of revenue in FY2025, down 219.7 pp from a year earlier.
  • Operating income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 6 analysts of -A$6.95M (+52.3%) for the fiscal year ending Jun 2026, a step up from the +25.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$12.82M— QoQ
Last fiscal yearJun 2025
-A$14.57M+25.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.2%——
1 year+25.6%+52.3%+26.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

AUD · from the income statement

Latest · FY2025
(14.57M) AUD
Year-over-year change
+25.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.6% is the highest of 4, against a peer median of -39.9%.
  • Operating income amounts to 268.0% of revenue for ATHE, versus a peer median of 238.4%.
ATHE Competitors
Operating Income for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYAIDyadic International, Inc.LTM Mar 2026-$7.09M USD-22.7%—238.4%
ATHEAlterity Therapeutics LimitedFY2025-A$14.57M AUD+25.6%—268.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$25.79M USD-39.9%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$41.42M USD-64.6%——
Peer median (excluding ATHE) —-39.9%—238.4%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.